Jonathan W. Goldman - Researcher Profile

Publications

3 shown

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon , Naiyer A. Rizvi , Rina Hui +24 more

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...

2015 New England Journal of Medicine 6054 citations

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares , Mikhail Dvorkin , Yuanbin Chen +97 more

2019 The Lancet 2014 citations

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu , Masahiro Tsuboi , Jie He +21 more

In patients with stage IB to IIIA <i>EGFR</i> mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who r...

2020 New England Journal of Medicine 1609 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 9,677
Institution: University of California, Los Angeles

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-4925-8243

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.